What is the expected CAGR for the cough hypersensitivity syndrome treatment market?

The cough hypersensitivity syndrome treatment market is expected to grow at a CAGR of 5.5% from 2019 to 2027.

What factors are driving the growth of this market?

The increase in the prevalence of chronic respiratory diseases and the number of smokers are significant factors driving market growth.

Which treatment options are expected to dominate the market?

Antitussive agents are anticipated to dominate the cough hypersensitivity syndrome treatment market.

How is the availability of over-the-counter medicines affecting the market?

The easy availability of over-the-counter medicines for cough is favoring the growth of retail pharmacies in this market.

Which region is expected to lead the cough hypersensitivity syndrome treatment market?

North America is projected to lead the global cough hypersensitivity syndrome treatment market.

Cough Hypersensitivity Treatment Market Growth Forecast to

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Cough Hypersensitivity Syndrome Treatment Market Expected to Grow at 5.5% CAGR

Transparency Market Research (TMR) has published a new report on the cough hypersensitivity syndrome treatment market for the forecast period of 2019–2027. According to the report, the global cough hypersensitivity syndrome treatment market was valued at ~US$ 7 Bn in 2018, and is projected to expand at a CAGR of 5.5% from 2019 to 2027.

Cough hypersensitivity syndrome encompasses various cough-related conditions arising from exposure to certain mechanical, thermal, and chemical environments.

The treatment for cough hypersensitivity syndrome includes prescribing and consumption of various classes of drugs that are mainly effective for three causes of chronic cough. These causes range from asthma and upper airway cough syndrome to reflux conditions.

Growth of the global cough hypersensitivity syndrome treatment market can be attributed to the rise in the prevalence of chronic respiratory diseases across the globe, which is leading to an increase in chronic cough conditions in the global population.

North America dominated the global cough hypersensitivity syndrome treatment market in 2018, and is projected to continue its dominance during the forecast period. This can be ascribed to the increase in the number of allergens leading to unexplained cough and high prevalence of chronic respiratory diseases in the region.

Asia Pacific is a lucrative cough hypersensitivity syndrome treatment market, due to high pollution levels, weather changes, and rise in the prevalence of chronic respiratory diseases in the region.

Increase in Prevalence of Chronic Respiratory Diseases and Number of Smokers Driving Market Growth

The prevalence of chronic respiratory diseases has been increasing at a rapid pace. These diseases include chronic obstructive pulmonary diseases, asthma, and several other allergic conditions, which lead to significant rise in chronic cough.

This rise in the prevalence of chronic respiratory diseases is propelling the growth of the global cough hypersensitivity syndrome market.

As per the International Study of Asthma and Allergy in Childhood, the annual prevalence of allergic rhinitis is considered to be approximately 30% in the adolescent population.

Increase in the number of smokers around the world is one of the major factors responsible for the growth of the cough hypersensitivity syndrome treatment market.

Unexplained chronic cough associated with Gastroesophageal Reflux Disease (GERD) is a major driver for the global cough hypersensitivity syndrome treatment market. GERD is one of the most common causes of chronic cough. Thus, the high prevalence of this condition is likely to drive the demand for its treatment.

Antitussive Agents to Dominate Cough Hypersensitivity Syndrome Treatment Market

Based on drug class, the global cough hypersensitivity syndrome treatment market has been segmented into antitussive agents, inhaled corticosteroids, short acting beta-2 agonists, anti-cholinergics, antihistamines, proton pump inhibitors, and others.

The antitussive agents drug class segment dominated the global cough hypersensitivity syndrome treatment market in 2018, and is projected to continue its dominance, in terms of revenue, during the forecast period.

Increase in the usage of antitussive agents for the treatment of cough hypersensitivity and ongoing research for the development of effective antitussive therapies are some of the major factors responsible for the growth of this segment.

Easy Availability of Over-the-counter Medicines for Cough Favoring Retail Pharmacies

In terms of distribution channel, the global cough hypersensitivity syndrome treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment dominated the global cough hypersensitivity syndrome treatment market. The easy availability of over-the-counter medicines at retail pharmacies for the treatment of cough is contributing to the expansion of the segment.

The online pharmacies segment is anticipated to expand at a high CAGR during the forecast period.

Rise in the awareness regarding online channels that sell cough medicines and convenience of product comparison on online platforms are some of the factors propelling the growth of the online pharmacies segment.

North America to Lead Global Cough Hypersensitivity Syndrome Treatment Market

In terms of region, the global cough hypersensitivity syndrome treatment market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America accounted for a major share of the global cough hypersensitivity syndrome treatment market in 2018, due to a rise in the prevalence of chronic respiratory diseases and increase in focus on R&D to develop a specific course of treatment for cough hypersensitivity.

Asia Pacific is a lucrative cough hypersensitivity syndrome treatment market, and this market is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to rising pollution levels, rapid weather changes leading to unexplained chronic cough, and the presence of major players in the region.

Competition Landscape

Pfizer, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH are some of the leading players in the global cough hypersensitivity syndrome treatment market that hold prominent market share.

The global cough hypersensitivity syndrome treatment market is fragmented in terms of number of players. Key players in the global market include Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, and Johnson & Johnson Consumer Inc.

Robust product pipeline for chronic cough treatment, heavy R&D investments on new products, and strategic collaborations & partnerships for business growth are some of the key strategies adopted by these players to grow in the global cough hypersensitivity syndrome treatment market.

More Trending Reports by Transparency Market Research –

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Cough Hypersensitivity Syndrome Treatment Market Size to Surge at the Cagr of 5.5% Form 2019 to 2027

Cough Hypersensitivity Syndrome Treatment Market Expected to Grow at 5.5% CAGR

Frequently Asked Questions about Cough Hypersensitivity Syndrome Treatment Market Size to Surge at the CAGR of 5.5% form 2019 to 2027